Raymond James Financial
JANX icon

Raymond James Financial’s Janux Therapeutics JANX Stock Holding History

Raymond James Financial’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-331
Closed -$7.65K – 5845
2025
Q2 		$7.65K Buy
+331
New +$8.72K ﹤0.01% 6034

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Raymond James Financial's JANX Position: Q3 2025 in Review

Raymond James Financial sold out of Janux Therapeutics (JANX) in Q3 2025, closing a stake of 331 shares — an estimated $7.65K sold.

Raymond James Financial first reported a position in JANX in Q2 2025 and held it in 1 quarter. The position peaked at $7.65K in Q2 2025. 174 funds tracked by Wall St. Rank hold JANX as of Q3 2025.

  • Raymond James Financial reported no remaining Janux Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 331 Janux Therapeutics shares in Q3 2025, an estimated $7.65K.
  • Raymond James Financial first reported a position in Janux Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Janux Therapeutics position peaked at $7.65K in Q2 2025.
  • 174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.